Effects of VitamIN K2 and D3 supplementaTion on PET/MRI in Carotid Artery Disease

Last updated: September 20, 2023
Sponsor: Academisch Ziekenhuis Maastricht
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Vascular Diseases

Hypercholesterolemia

Carotid Artery Disease

Treatment

Placebo

MK-7 and vitamin D3

Clinical Study ID

NCT04010578
NL69450.068.19
  • Ages > 18
  • All Genders

Study Summary

Atherosclerosis is a disease of the arteries and is the result of various factors such as high blood cholesterol or diabetes, which lead to accumulations of fats, cells, and calcium deposits (i.e. plaques). It has been shown that people with a rapid increase in the amount of calcium deposits have a higher risk for stroke and heart attack than people with a decreased amount.

Previous scientific research has shown that a protein called Matrix Gla Protein plays an important role in the prevention of calcification. This protein works well only if there is enough Vitamin K in the blood vessels. In a large human studies, it has been shown that especially MK-7 (a form of Vitamin K2) is best absorbed by blood vessels. Moreover, studies suggest positive effects of vitamin D (especially D3) on vitamin K-dependent metabolism.

Over the last years, fluorine-18 sodium fluoride (18F-NaF) positron emission tomography (PET) emerged as a reliable clinical imaging tool able to detect micro-calcification in the blood vessels. Therefore, the present study will use 18F-NaF PET in combination with magnetic resonance imaging (MRI) to assess the influence of vitamin K and D supplementation in the development of arterial micro-calcification in the context of atherosclerosis.

The present study would like to confirm that MK-7 and vitamin D3 supplementation induces a significant reduction in the degree of micro-calcification from carotid artery disease patients, when comparing to a placebo, after 3 months.

This will be a prospective double blind randomised controlled feasibility study, in which one group will receive a MK-7 and vitamin D3 supplementation compared to a control group receiving a placebo.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Asymptomatic carotid artery disease on at least one side with a degree of stenosis > 25% (according to on the ECST criteria). If the patient has a symptomatic carotidartery disease on the contra-lateral side, he/she will still be included in the study,if intensified medical treatment for this symptomatic stenosis (e.g. statins,antiplatelet medication) was started ≥ 6 month before inclusion of the patient. Thisprotocol was chosen in order to widely assure a stable situation on the plaque(s),which avoids an overspill from this medication on the assumed effects of the MK-7 andvitamin D3 supplementation.
  • Age older than 18 years
  • Signed informed consent provided

Exclusion

Exclusion Criteria:

  • Antiplatelet or cholesterol lowering medication started within the past 6 months
  • Chronic or paroxysmal atrial fibrillation
  • Presence or scheduled coronary or carotid revascularisation procedure (e.g. stentimplantation, coronary artery bypass graft, balloon-dilatation, endarterectomy,angioplasty)
  • History of myocardial infarction or stroke
  • Malignant disease (except for treated basal-cell or squamous cell carcinoma)
  • Use of vitamin K antagonists or any other anticoagulation treatment
  • A life-expectancy < 1 year
  • Claustrophobia
  • Presence of a pacemaker, intra-cardiac defibrillator, or metallic implant (e.g.vascular clip, neuro-stimulator, cochlear implant)
  • Body weight > 130kg or body habitus that does not fit into the gantry
  • Pregnancy or wish to become pregnant in the near future
  • Breast feeding
  • (History of) metabolic or gastrointestinal disease
  • Use of vitamin K or D containing supplements or vitamin K-rich foods (i.e. soya)
  • Chronic inflammatory disease
  • Systemic treatment or topical treatment likely to interfere with evaluation of thestudy parameters
  • Corticoid treatment
  • Participation in a clinical study more recently than one month before the currentstudy

Study Design

Total Participants: 52
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
January 01, 2024
Estimated Completion Date:
April 01, 2025